Table 2.

Clinical studies of curcumin used in the treatment of oxidative associated liver diseases.

Dose	Study Design	No. of Patients	Duration of Treatment	Result	Reference
1000 mg/day	Patients with NAFLD were randomly assigned to the curcumin (n = 44) or placebo group (n = 43)	87	8 weeks	↓ the body mass index, AST, ALT, SGOT, SGPT	[144]
500 mg/day	Patients with NAFLD were randomly assigned to the curcumin (n = 40) or placebo group (n = 40)	80	8 weeks	↓ Total cholesterol, LDL-C, ALT, AST ↑ HDL-C	[143]